This is evidenced by a significantly higher prevalence of pathogenic EGFR gene mutations in Chinese patients with non-small cell lung cancer (NSCLC) compared to other ethnic groups (41), underscoring the necessity for precision-based prevention and control strategies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.